Annovis Bio Cash And Equivalents vs. Return On Asset

ANVS Stock  USD 5.66  0.07  1.22%   
Considering Annovis Bio's profitability and operating efficiency indicators, Annovis Bio may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in January. Profitability indicators assess Annovis Bio's ability to earn profits and add value for shareholders. At this time, Annovis Bio's ROIC is comparatively stable compared to the past year. Income Quality is likely to gain to 0.76 in 2024, despite the fact that Book Value Per Share is likely to grow to (0.82).
For Annovis Bio profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Annovis Bio to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Annovis Bio utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Annovis Bio's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Annovis Bio over time as well as its relative position and ranking within its peers.
  
Check out Trending Equities.
For more information on how to buy Annovis Stock please use our How to Invest in Annovis Bio guide.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Annovis Bio. If investors know Annovis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Annovis Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(4.22)
Return On Assets
(1.55)
Return On Equity
(5.97)
The market value of Annovis Bio is measured differently than its book value, which is the value of Annovis that is recorded on the company's balance sheet. Investors also form their own opinion of Annovis Bio's value that differs from its market value or its book value, called intrinsic value, which is Annovis Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Annovis Bio's market value can be influenced by many factors that don't directly affect Annovis Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Annovis Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Annovis Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Annovis Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Annovis Bio Return On Asset vs. Cash And Equivalents Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Annovis Bio's current stock value. Our valuation model uses many indicators to compare Annovis Bio value to that of its competitors to determine the firm's financial worth.
Annovis Bio is rated below average in cash and equivalents category among its peers. It is rated below average in return on asset category among its peers . Return On Assets is likely to gain to -5.23 in 2024. Comparative valuation analysis is a catch-all technique that is used if you cannot value Annovis Bio by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Annovis Return On Asset vs. Cash And Equivalents

Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.

Annovis Bio

Cash

 = 

Bank Deposits

+

Liquidities

 = 
35.97 M
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.

Annovis Bio

Return On Asset

 = 

Net Income

Total Assets

 = 
-1.55
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.

Annovis Return On Asset Comparison

Annovis Bio is currently under evaluation in return on asset category among its peers.

Annovis Bio Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Annovis Bio, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Annovis Bio will eventually generate negative long term returns. The profitability progress is the general direction of Annovis Bio's change in net profit over the period of time. It can combine multiple indicators of Annovis Bio, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Operating Income-45 M-42.8 M
Net Loss-41.7 M-39.6 M
Income Before Tax-56.2 M-53.4 M
Total Other Income Expense Net-11.2 M-10.6 M
Net Loss-13 M-12.4 M
Net Loss-56.2 M-53.4 M
Income Tax Expense-45 K-47.3 K
Net Interest Income675.9 K709.7 K
Interest Income675.9 K709.7 K
Non Operating Income Net Other33.1 K31.4 K
Change To Netincome5.4 M5.7 M
Net Loss(6.23)(5.92)
Income Quality 0.71  0.76 
Net Income Per E B T 0.89  0.62 

Annovis Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Annovis Bio. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Annovis Bio position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Annovis Bio's important profitability drivers and their relationship over time.

Use Annovis Bio in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Annovis Bio position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Annovis Bio will appreciate offsetting losses from the drop in the long position's value.

Annovis Bio Pair Trading

Annovis Bio Pair Trading Analysis

The ability to find closely correlated positions to Annovis Bio could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Annovis Bio when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Annovis Bio - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Annovis Bio to buy it.
The correlation of Annovis Bio is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Annovis Bio moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Annovis Bio moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Annovis Bio can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Annovis Bio position

In addition to having Annovis Bio in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run SRI Sustainable Growth Thematic Idea Now

SRI Sustainable Growth
SRI Sustainable Growth Theme
Socially responsible investments that include companies making a positive, sustainable or social impact and exclude those making a negative impact. The SRI Sustainable Growth theme has 47 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize SRI Sustainable Growth Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for Annovis Stock Analysis

When running Annovis Bio's price analysis, check to measure Annovis Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Annovis Bio is operating at the current time. Most of Annovis Bio's value examination focuses on studying past and present price action to predict the probability of Annovis Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Annovis Bio's price. Additionally, you may evaluate how the addition of Annovis Bio to your portfolios can decrease your overall portfolio volatility.